Investors with losses are encouraged to contact the firm before April 20, 2021; click here to submit trade information
LOS ANGELES, April 14, 2021 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Immunovant, Inc. (NASDAQ: IMVT) investors that acquired shares between October 2, 2019 and February 1, 2021. Investors have until April 20, 2021 to seek an active role in this litigation.
Investors are encouraged to contact attorney Lesley F. Portnoy, to determine eligibility to participate in this action, by phone 310-692-8883 or email, or click here to join the case.
On February 2, 2021, Immunovant announced a “voluntary pause of dosing in its ongoing clinical trials for IMVT-1401”. Immunovant admitted that it "has become aware of a physiological signal consisting of elevated total cholesterol and LDL levels in IMVT-1401-treated patients" and “out of an abundance of caution, the Company has decided to voluntarily pause dosing in ongoing clinical studies in both TED and in Warm Autoimmune Hemolytic Anemia, in order to inform patients, investigators, and regulators as well as to modify the monitoring program." Shares of Immunovant fell by more than 42% on the same day, based on this news.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 20, 2021.
Please visit our website to review more information and submit your transaction information.
The Portnoy Law Firm represents investors in pursuing claims arising from corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.
Lesley F. Portnoy, Esq.
Admitted CA and NY Bar
lesley@portnoylaw.com
310-692-8883
www.portnoylaw.com
Attorney Advertising